BioSpace News Archive

Acepodia, today announced that an article describing the efficacy profile of ACE1702, Acepodia’s novel, off-the-shelf natural killer (NK) cell therapy against HER2-expressing solid tumors, was published in the journal Cancers.

Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that it has completed enrollment in its Phase 3 study of lirentelimab in patients with eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc.

Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Raymond James 2021 Human Health Innovation Conference on Monday, June 21, 2021 at 8:40 a.m. (ET).

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it will be holding a Virtual Investor Event on Tuesday, June 22, 2021, at 9:00 a.m. - 11:00 a.m. EDT / 3:00 p.m. - 5:00 p.m. CEST.

Continued Execution on Strategy to Advance Nirogacestat as a BCMA Potentiator Across Modalities

Poster published at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting shows the final 5 year safety data from the Phase IIb breast cancer clinical trial.

Pre-clinical Data Support Plans to Advance CFT8919 to Clinical Development with IND Submission Expected in mid-2022 and Clinical Trial Initiation Expected by YE 2022

The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more than the planned 464

Autobahn Labs, an early-stage drug discovery incubator, announced a new strategic venture collaboration with Cold Spring Harbor Laboratory.